USA - NASDAQ:SERA - US81749D1072 - Common Stock
SERA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. SERA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SERA is quite expensive at the moment. It does show a decent growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.27% | ||
| ROE | -37.1% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.99 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.73 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SERA (10/28/2025, 8:21:41 PM)
3.75
+0.01 (+0.27%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1321.53 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.62 | ||
| P/tB | 1.64 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.27% | ||
| ROE | -37.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 76.79% | ||
| Cap/Sales | 615.74% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.73 | ||
| Altman-Z | -0.99 |
ChartMill assigns a fundamental rating of 3 / 10 to SERA.
ChartMill assigns a valuation rating of 0 / 10 to SERA PROGNOSTICS INC-A (SERA). This can be considered as Overvalued.
SERA PROGNOSTICS INC-A (SERA) has a profitability rating of 1 / 10.
The financial health rating of SERA PROGNOSTICS INC-A (SERA) is 5 / 10.
The Earnings per Share (EPS) of SERA PROGNOSTICS INC-A (SERA) is expected to grow by 21.7% in the next year.